Newave Pharmaceutical LLC. and Guangzhou Lupeng Pharmaceutical Co., Ltd. have identified isoquinolines acting as epidermal growth factor receptor (EGFR) (mutant) inhibitors reported to be useful for the treatment of cancer, inflammation and autoimmune disease.